Please ensure Javascript is enabled for purposes of website accessibility

Pliant Therapeutics Up 33% on IPO Pricing

By Brian Orelli, PhD – Jun 3, 2020 at 5:24PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors are excited about the biotech's prospects, but the company still has a long road ahead.

Pliant Therapeutics (PLRX 0.63%) closed up 33% today to $21.30, after pricing its initial public offering (IPO) at $16 per share. At one point today, shares were as high as $25.

Pliant raised $144 million in the IPO, which priced at the high end of the $14 to $16 range the company had set for itself. There was clearly substantial demand for the IPO, since it was upsized to 9 million shares from an initial plan to sell just 6 million shares.

Finger touching a screen that says IPO

Image source: Getty Images.

The biotech is testing its lead clinical candidate, PLN-74809, as a treatment for idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC). IPF is a lung disease and PSC affects the liver, but the connection is that both diseases are facilitated by inflammation and scarring caused by the immune system. PLN-74809 works by inhibiting integrins that are responsible for activating immune cells that cause the damage. A phase 2a clinical trial in IPF is under way, and Pliant plans to start a phase 2a study in PSC in the second half of 2020.

Pliant is also developing PLN-1474 in conjunction with Novartis (NVS -0.73%) for the treatment of liver fibrosis in patients with non-alcoholic steatohepatitis. The companies started a phase 1 study of the drug last month.

Last year, Novartis paid $80 million up front, including an equity investment, when it licensed PLN-1474 and up to three additional drugs targeting integrins. Novartis also participated in the IPO, purchasing an additional $10 million of shares in a private placement at the IPO price.

Pliant also has a couple of additional preclinical assets, but given their early stage, it's hard to assign much value to those pipeline candidates. Of course, at a market cap around $750 million, the biotech doesn't need much beyond PLN-74809 and PLN-1474 to support its valuation.

While its clinical-stage valuation seems reasonable, investors should keep in mind that it'll be while -- multiple years -- before Pliant will be able to generate revenue from an approved drug, so it's most appropriate for a long-term investor.

Brian Orelli and The Motley Fool have no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Pliant Therapeutics, Inc. Stock Quote
Pliant Therapeutics, Inc.
PLRX
$20.89 (0.63%) $0.13
Novartis AG Stock Quote
Novartis AG
NVS
$76.01 (-0.73%) $0.56

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
326%
 
S&P 500 Returns
102%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/01/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.